Personalized Medicine of Urate-Lowering Therapy for Gout
, 2020 Gout is a common and complex form of arthritis that is characterised with hyperuricaemia. It is required urate-lowering therapy (ULT) for lifelong management. ULT includes decreasing uric acid product in serum, increasing renal urate excretion and promoting uric acid to allantoin for excretion.
Zhang, Y, Yan, D
openaire +4 more sources
Urate-Lowering Therapy in Moderate to Severe Chronic Kidney Disease [PDF]
The Permanente Journal, 2018 Hyperuricemia is an independent risk factor for progression of kidney disease.To determine whether lowering serum uric acid level (sUA) to below 6 mg/dL (target) improves mild to moderate chronic kidney disease (CKD) and whether CKD stage influences the benefit of lowering sUA to target.Retrospective epidemiologic cohort study conducted over 8 years ...
Gerald, Levy +3 more
openaire +2 more sources
Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST):a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia [PDF]
, 2014 Introduction: Gout affects 2.5% of the UK's adult population and is now the most common type of inflammatory arthritis. The long-term management of gout requires reduction of serum urate levels and this is most often achieved with use of xanthine oxidase
Annemans +16 more
core +6 more sources
Factors associated with initiation and persistence of urate-lowering therapy [PDF]
Arthritis Research & Therapy, 2017 Gout is the most common inflammatory arthritic disease and is caused by crystal deposition secondary to persistent hyperuricemia. Etiological treatment with urate-lowering therapy (ULT) has been available since the 1950s but previous studies have demonstrated suboptimal degree of treatment.
Mats Dehlin +5 more
openaire +2 more sources
Principles of urate-lowering therapy: eight steps to success
Modern Rheumatology Journal, 2023 Treatment of such a serious systemic disease as gout is often carried out incorrectly, despite the presence of a large number of recommendations and drugs. The reluctance of some doctors to follow current recommendations for the management of patients with gout is one of the factors for poor adherence of patients to therapy. The review considers modern
O. V. Zhelyabina +2 more
openaire +2 more sources
Adherence with urate-lowering therapies for the treatment of gout [PDF]
Arthritis Research & Therapy, 2009 Abstract Introduction Adherence to urate-lowering drugs (ULDs) has not been well evaluated among those with gout. Our aim was to assess the level and determinants of non-adherence with ULDs prescribed for gout.
Harrold, Leslie R +6 more
openaire +3 more sources
Effects of Discontinuation of Urate-Lowering Therapy: A Systematic Review [PDF]
Journal of General Internal Medicine, 2017 Urate-lowering therapy (ULT) is associated with low rates of adherence, leading to a potential risk of relapse of gouty arthritis, tophi, or urolithiasis. Our main aim was to identify the recurrence of gouty arthritis, tophi, or urolithiasis after discontinuation of ULT.
Beslon, Virginie +5 more
openaire +4 more sources
Using serum urate as a validated surrogate end point for flares in patients with gout:protocol for a systematic review and meta-regression analysis [PDF]
, 2016 INTRODUCTION: Gout is the most common inflammatory arthritis in men over 40 years of age. Long-term urate-lowering therapy is considered a key strategy for effective gout management.
Birger Morillon, Melanie +7 more
core +2 more sources
Arthritis Care &Research, EarlyView.Objective Despite well‐described biologic causes, the public views unhealthy lifestyle choices as the primary cause of gout. This study investigated how causal beliefs about gout influence the public's views about its management. Methods In a randomized study, 201 members of the public viewed one of two 2‐minute videos about gout.
Rachel Murdoch +6 more
wiley +1 more source
Patients Prescribed Anakinra for Acute Gout Have Baseline Increased Burden of Hyperuricemia, Tophi, and Comorbidities, and Ultimate All-Cause Mortality. [PDF]
, 2019 Objective:The interleukin-1 (IL-1) receptor antagonist anakinra is an effective, off-label option in acute gout flares, when conventional therapy options are narrowed.
Pedersen, Brian +2 more
core